Clinical trials
Observational Atherosclerosis trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2024 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 19 |
| Completed | 6 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Xuanwu Hospital, Beijing | 3 |
| Peking Union Medical College Hospital | 2 |
| Shanghai Jiao Tong University School of Medicine | 2 |
| Tsinghua University | 2 |
| Amgen | 1 |
| Beijing Hospital | 1 |
| China National Center for Cardiovascular Diseases | 1 |
| Chongqing Medical University | 1 |
| Li Min | 1 |
| Ministry of Health, China | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atherosclerosis | 32 |
| Cardiovascular Diseases | 5 |
| Stroke | 5 |
| Coronary Artery Disease | 4 |
| Ischemic Stroke | 4 |
| Carotid Stenosis | 2 |
| Coronary Disease | 2 |
| Diabetes Mellitus | 2 |
| Hypertension | 2 |
| Ischemic Attack, Transient | 2 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.